At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 197 enrolled
Drug / intervention
Tamoxifen +2 moredrug
Likely dose
Tamoxifen 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients
In Brief
A Phase 3 clinical trial evaluating Tamoxifen, Anastrazole (Arimidex), and 1 other intervention for Breast Cancer. Completed, enrolled 197 participants across 4 sites.
Detailed Summary
The purpose of this multi-centre, randomised, double-blind, parallel-group study is to compare efficacy and safety between anastrozole and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for premenopausal breast cancer patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedJan 2008
Primary CompletionNov 2009
Study CompletionDec 2010
TodayJul 2026
First PostedJan 31, 2008
Enrollment StartOct 1, 2007
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.4 years ago
Interventions
Tamoxifendrug
20 mg once daily oral dose
Anastrazole (Arimidex)drug
1 mg once daily oral dose
Goserelin acetate (Zoladex)drug
3.6mg/month depot injection